Page 20«..10..19202122..3040..»

One World Pharma Secures $3 Million Investment Commitment From ISIAH International

By Dr. Matthew Watson

LAS VEGAS, NV, Feb. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- One World Pharma Inc. (OTC: OWPC), (“OWP” or the “Company”), a U.S. based, fully licensed, pure-play hemp and cannabis ingredient producer in Colombia, is pleased to announce an agreement with ISIAH International, LLC, the holding company of its CEO, Isiah Thomas, to invest $3 million into One World Pharma, Inc.

Read the original post:
One World Pharma Secures $3 Million Investment Commitment From ISIAH International

To Read More: One World Pharma Secures $3 Million Investment Commitment From ISIAH International
categoriaGlobal News Feed commentoComments Off on One World Pharma Secures $3 Million Investment Commitment From ISIAH International | dataFebruary 10th, 2021
Read All

Lee’s Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Breakthrough Therapy Designation…

By Dr. Matthew Watson

HONG KONG and SAN DIEGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- China Oncology Focus Limited (COF), an affiliate of Lee's Pharmaceutical Holdings Limited (Lee's Pharma, HKEX: 950), and Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE), today announced that its anti-PD-L1 antibody, socazolimab, licensed from Sorrento to COF for the greater China territory, has been granted breakthrough therapy designation (BTD) by the China National Medical Products Administration (NMPA) to treat recurrent or metastatic cervical cancer.

Go here to see the original:
Lee’s Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Breakthrough Therapy Designation...

To Read More: Lee’s Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Breakthrough Therapy Designation…
categoriaGlobal News Feed commentoComments Off on Lee’s Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Breakthrough Therapy Designation… | dataFebruary 10th, 2021
Read All

Agenus Announces Agenus Insights – Virtual R&D Miniseries

By Dr. Matthew Watson

LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will host its inaugural Agenus Insights on “Optimally Targeting TIGIT” on Thursday, February 11, 2021 at 1:00 p.m. ET.

Visit link:
Agenus Announces Agenus Insights - Virtual R&D Miniseries

To Read More: Agenus Announces Agenus Insights – Virtual R&D Miniseries
categoriaGlobal News Feed commentoComments Off on Agenus Announces Agenus Insights – Virtual R&D Miniseries | dataFebruary 10th, 2021
Read All

Hangzhou Chance Pharmaceuticals Expands Pipeline with In-Licensing of AER901 from Aerami Therapeutics

By Dr. Matthew Watson

HANGZHOU, China, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Hangzhou Chance Pharmaceuticals (“Chance”), a clinical-stage biotechnology company focusing on discovering, developing and commercializing transformative inhalation therapies for the world’s most debilitating diseases, and Aerami Therapeutics, Inc. (“Aerami” ), a clinical stage biopharmaceutical company developing inhalation therapies to treat severe respiratory and chronic diseases, announced today that they have signed an exclusive license and development agreement to develop and commercialize Aerami’s drug device combination product candidate (“AER-901”) for the treatment of Pulmonary Arterial Hypertension (“PAH”) in Greater China region (Mainland, Hong Kong, Macau and Taiwan).

Read more here:
Hangzhou Chance Pharmaceuticals Expands Pipeline with In-Licensing of AER901 from Aerami Therapeutics

To Read More: Hangzhou Chance Pharmaceuticals Expands Pipeline with In-Licensing of AER901 from Aerami Therapeutics
categoriaGlobal News Feed commentoComments Off on Hangzhou Chance Pharmaceuticals Expands Pipeline with In-Licensing of AER901 from Aerami Therapeutics | dataFebruary 10th, 2021
Read All

The Capital Group holds 10.03% of Galapagos shares

By Dr. Matthew Watson

Mechelen, Belgium; 9 February 2021; 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from The Capital Group Companies, Inc.

Read the original:
The Capital Group holds 10.03% of Galapagos shares

To Read More: The Capital Group holds 10.03% of Galapagos shares
categoriaGlobal News Feed commentoComments Off on The Capital Group holds 10.03% of Galapagos shares | dataFebruary 10th, 2021
Read All

Infant Bacterial Therapeutics today announces that new patent protection is granted in Japan

By Dr. Matthew Watson

Infant Bacterial Therapeutics AB today announces that the Japan Patent Office has issued a decision to grant a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of NEC and improvement of feeding tolerance in preterm infants.

See original here:
Infant Bacterial Therapeutics today announces that new patent protection is granted in Japan

To Read More: Infant Bacterial Therapeutics today announces that new patent protection is granted in Japan
categoriaGlobal News Feed commentoComments Off on Infant Bacterial Therapeutics today announces that new patent protection is granted in Japan | dataFebruary 10th, 2021
Read All

Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to…

By Dr. Matthew Watson

PRESS RELEASE

Read the original here:
Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to...

To Read More: Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to…
categoriaGlobal News Feed commentoComments Off on Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to… | dataFebruary 10th, 2021
Read All

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February and March

By Dr. Matthew Watson

CANTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the following upcoming investor conferences:

View original post here:
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February and March

To Read More: Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February and March
categoriaGlobal News Feed commentoComments Off on Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February and March | dataFebruary 10th, 2021
Read All

Zealand Pharma to participate in SVB Leerink 9th Annual Global Healthcare Conference

By Dr. Matthew Watson

Press Release – No. 7 / 2021

See the rest here:
Zealand Pharma to participate in SVB Leerink 9th Annual Global Healthcare Conference

To Read More: Zealand Pharma to participate in SVB Leerink 9th Annual Global Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Zealand Pharma to participate in SVB Leerink 9th Annual Global Healthcare Conference | dataFebruary 10th, 2021
Read All

Tonix Pharmaceuticals Holdings Corp. Closes $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules

By Dr. Matthew Watson

CHATHAM, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced registered direct offering, priced at-the-market, with gross proceeds of approximately $70.0 million before deducting fees and other estimated offering expenses. The Company sold 58,333,334 shares of common stock at $1.20 per share.

Follow this link:
Tonix Pharmaceuticals Holdings Corp. Closes $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules

To Read More: Tonix Pharmaceuticals Holdings Corp. Closes $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules
categoriaGlobal News Feed commentoComments Off on Tonix Pharmaceuticals Holdings Corp. Closes $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules | dataFebruary 10th, 2021
Read All

Codexis Announces Expansion to New Facility to Accommodate Next Stage of Growth

By Dr. Matthew Watson

REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, announced today it will be expanding its operations into a new 36,000 square foot facility in San Carlos, CA under a ten year lease. This facility will provide space for additional research and development laboratories and related office space.

Original post:
Codexis Announces Expansion to New Facility to Accommodate Next Stage of Growth

To Read More: Codexis Announces Expansion to New Facility to Accommodate Next Stage of Growth
categoriaGlobal News Feed commentoComments Off on Codexis Announces Expansion to New Facility to Accommodate Next Stage of Growth | dataFebruary 10th, 2021
Read All

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update

By Dr. Matthew Watson

U.S. FDA reviewing premarket approval (PMA) submission for LungFitTM PH to treat persistent pulmonary hypertension of the newborn (PPHN), as Company prepares for commercialization

See the original post:
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update

To Read More: Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update
categoriaGlobal News Feed commentoComments Off on Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update | dataFebruary 10th, 2021
Read All

Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares

By Dr. Matthew Watson

CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the closing of its previously announced initial public offering of 9,828,017 shares of its common stock, plus an additional 1,474,202 shares sold pursuant to the full option exercised by the underwriters, at a price to the public of $18.00 per share. The aggregate gross proceeds to Vor from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Vor, were approximately $203.4 million. The shares began trading on the Nasdaq Global Market on Friday, February 5, 2021 under the ticker symbol “VOR”.

Continued here:
Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares

To Read More: Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares
categoriaGlobal News Feed commentoComments Off on Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares | dataFebruary 10th, 2021
Read All

Angion Biomedica Corp. Announces Closing of $117 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of…

By Dr. Matthew Watson

UNIONDALE, N.Y., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced the closing of $117 million in gross proceeds from its previously announced initial public offering and concurrent private placement.

More:
Angion Biomedica Corp. Announces Closing of $117 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of...

To Read More: Angion Biomedica Corp. Announces Closing of $117 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of…
categoriaGlobal News Feed commentoComments Off on Angion Biomedica Corp. Announces Closing of $117 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of… | dataFebruary 10th, 2021
Read All

GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of…

By Dr. Matthew Watson

Lille, France; Cambridge, MA; February 09, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced that the positive results from the Phase 2 clinical trial evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC) with incomplete response to ursodeoxycholic acid (UDCA) have been published in the Journal of Hepatology.

Read the original here:
GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of...

To Read More: GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of…
categoriaGlobal News Feed commentoComments Off on GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of… | dataFebruary 10th, 2021
Read All

Revive Therapeutics Receives Receipt for Final Short-Form Prospectus for Previously Announced $20 Million Bought Deal Public Offering

By Dr. Matthew Watson

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

See the article here:
Revive Therapeutics Receives Receipt for Final Short-Form Prospectus for Previously Announced $20 Million Bought Deal Public Offering

To Read More: Revive Therapeutics Receives Receipt for Final Short-Form Prospectus for Previously Announced $20 Million Bought Deal Public Offering
categoriaGlobal News Feed commentoComments Off on Revive Therapeutics Receives Receipt for Final Short-Form Prospectus for Previously Announced $20 Million Bought Deal Public Offering | dataFebruary 10th, 2021
Read All

FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma

By Dr. Matthew Watson

FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma

Read the original here:
FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma

To Read More: FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
categoriaGlobal News Feed commentoComments Off on FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma | dataFebruary 10th, 2021
Read All

Andy Hurley Named Agenus Chief Commercial Officer

By Dr. Matthew Watson

LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the appointment of Andy Hurley as its Chief Commercial Officer.

Read more:
Andy Hurley Named Agenus Chief Commercial Officer

To Read More: Andy Hurley Named Agenus Chief Commercial Officer
categoriaGlobal News Feed commentoComments Off on Andy Hurley Named Agenus Chief Commercial Officer | dataFebruary 10th, 2021
Read All

ObsEva Provides Business Outlook for 2021

By Dr. Matthew Watson

Read more:
ObsEva Provides Business Outlook for 2021

To Read More: ObsEva Provides Business Outlook for 2021
categoriaGlobal News Feed commentoComments Off on ObsEva Provides Business Outlook for 2021 | dataFebruary 10th, 2021
Read All

Basilea reports positive topline results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene fusion-positive patients with bile duct cancer…

By Dr. Matthew Watson

Basel, Switzerland, February 10, 2021

The rest is here:
Basilea reports positive topline results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene fusion-positive patients with bile duct cancer...

To Read More: Basilea reports positive topline results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene fusion-positive patients with bile duct cancer…
categoriaGlobal News Feed commentoComments Off on Basilea reports positive topline results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene fusion-positive patients with bile duct cancer… | dataFebruary 10th, 2021
Read All

Page 20«..10..19202122..3040..»